Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 13/20 | 0.62 |
| ▸ | ABCC8 | Q09428 | 13/20 | 0.62 |
| ▸ | KCNJ11 | Q14654 | 13/20 | 0.62 |
| ▸ | KCNJ8 | Q15842 | 13/20 | 0.62 |
| ▸ | MET | P08581 | 5/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10212435 | 0.83 | ABCC9 (0.42) | ABCC9ABCC8KCNJ11KCNJ8MET | |
| SCHEMBL561467 | 0.82 | ABCC9 (0.62) | ABCC9ABCC8KCNJ11KCNJ8MET | |
| SCHEMBL1583361 | 0.81 | MET (0.80) | METPOLBMAPK1SMN1; SMN2RPS6KA3 | |
| SCHEMBL562367 | 0.80 | MET (0.61) | ABCC9ABCC8KCNJ11KCNJ8MET | |
| SCHEMBL1583928 | 0.75 | MET (1.00) | METPOLBMAPK1SMN1; SMN2RPS6KA3 | |
| SCHEMBL9906873 | 0.74 | MET (0.65) | METPOLBMAPK1SMN1; SMN2RPS6KA3 | |
| SCHEMBL2011081 | 0.73 | MET (0.67) | ABCC9ABCC8KCNJ11KCNJ8MET | |
| SCHEMBL2009516 | 0.73 | MET (0.67) | METPOLBMAPK1SMN1; SMN2RPS6KA3 | |
| SCHEMBL1982875 | 0.73 | MET (0.63) | METPOLBMAPK1SMN1; SMN2RPS6KA3 | |
| SCHEMBL4996162 | 0.72 | MET (0.66) | METPOLBMAPK1SMN1; SMN2RPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759341-B2 | Bi- and tricyclic indazole-substituted 1,4-dihydropyridine derivatives and uses thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-06-24 | — | — | US | disclosed |
| US-8759341-B2 | Bi- and tricyclic indazole-substituted 1,4-dihydropyridine derivatives and uses thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-06-24 | — | — | US | disclosed |
| EP-2398790-B1 | BI- AND TRICYCLIC INDAZOLE-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND USES THEREOF | BAYER IP GMBH (DE) | 2013-07-03 | — | — | EP | disclosed |
| EP-2398790-B1 | BI- AND TRICYCLIC INDAZOLE-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND USES THEREOF | BAYER IP GMBH (DE) | 2013-07-03 | — | — | EP | disclosed |
| US-20120035409-A1 | BI- AND TRICYCLIC INDAZOLE-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND USES THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-09 | — | — | US | disclosed |
| US-20120035409-A1 | BI- AND TRICYCLIC INDAZOLE-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND USES THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-09 | — | — | US | disclosed |
| WO-2010094405-A1 | BI- AND TRICYCLIC INDAZOLE-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND USES THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035409-A1 | BI- AND TRICYCLIC INDAZOLE-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND USES THEREOF | MET, RET, ERBB2 | ABCC9 3756/4885ABCC8 3709/4885KCNJ11 4372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.